SPC528
Acalabrútiníb eða lyfjafræðilega tækt salt þess, í samsetningu með venetóclaxi veljanlega með eða án obínútuzumabi.
Status:
UmsóknApplication date:
1.12.2025Application published:
14.1.2026
Medicine name:
CALQUENCEMedicine for children:
No
Timeline
Today
1.12.2025Application
14.1.2026Publication
Marketing license
Foreign authorization number:
EU/1/20/1479Date:
2.6.2025
Owner
Name:
Acerta Pharma B.V.Address:
Kloosterstraat 9, 5349 AB Oss NL
Agent
Name:
Kjartan Ragnars, hrl.Address:
Hrauntungu 66, 200 Kópavogi
Patent
Number:
EP3179991
Deadlines
TypeDeadline until
Type: Formgallafrestur, fyrsti
Deadline until: 05.04.2026